Perioperative Durvalumab for Gastric Cancer Treatment
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the availability of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United States.
The virus spreads thru close contact with infected individuals, much like the common cold or flu. Symptoms can include a runny nose, cough, fever, and shortness of breath. Older adults are particularly vulnerable because their immune systems weaken with age, making them less able to fight off the infection.
The Arexvy Vaccine: How It Works and What the Data Shows
Arexvy,developed by GSK,is a recombinant subunit vaccine. This means it doesn’t use a live virus. Rather,it contains a stabilized prefusion F protein,a key component of the RSV virus that triggers an immune response.The vaccine works by teaching the body to recognize and fight off the RSV virus if exposed.
Data published in the New england Journal of Medicine on October 23, 2025, provides compelling evidence of Arexvy’s real-world effectiveness.A large-scale study involving over 125,000 participants demonstrated a vaccine efficacy of 66.3% against RSV-associated lower respiratory tract disease (LRTD) with three or more symptoms. Furthermore, the vaccine showed an efficacy of 73.5% against severe LRTD, defined as illness requiring hospitalization.
The study also examined the vaccine’s safety profile. While some participants experienced mild side effects, such as pain at the injection site, fatigue, and muscle aches, serious adverse events were rare and not directly linked to the vaccine.
| Outcome | Vaccine efficacy (%) |
|---|---|
| RSV-associated LRTD (≥3 symptoms) | 66.3 |
| Severe RSV-associated LRTD (hospitalization) | 73.5 |
Who Should Get the RSV vaccine?
The Centers for Disease control and Prevention (CDC) recommends that adults aged 60 years and older may recieve a single dose of an RSV vaccine, based on shared clinical decision-making with their healthcare provider. This means that individuals should discuss the benefits and risks of vaccination with their doctor to determine if it’s the right choice for them.
Factors to consider include individual health status, risk of RSV exposure, and personal preferences. those with underlying medical conditions, such as heart disease or lung disease, may benefit particularly from vaccination.
Beyond Arexvy: Other RSV Vaccine Developments
While Arexvy was the first RSV vaccine approved for older adults, other vaccines are also in development. Pfizer’s Abrysvo received FDA approval shortly after Arexvy,offering another option for protecting seniors against RSV